Terkild Brink Buus
@terkild.bsky.social
Assistant Professor intrigued by skin immunology, T cell lymphoma, S. aureus-T cell interactions and single-cell analyses at University of Copenhagen @ucph.bsky.social
Pinned
Terkild Brink Buus
@terkild.bsky.social
· Jun 19
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
Glad to see our article on how cancer drugs and bacterial (S. aureus) infections can affect co-existing malignant subclones very differently in cutaneous T-cell lymphoma.
Thank you Cancer Discovery (@aacrjournals.bsky.social) for the beautiful title-page graphics!
Thank you Cancer Discovery (@aacrjournals.bsky.social) for the beautiful title-page graphics!
November 6, 2025 at 10:31 AM
Glad to see our article on how cancer drugs and bacterial (S. aureus) infections can affect co-existing malignant subclones very differently in cutaneous T-cell lymphoma.
Thank you Cancer Discovery (@aacrjournals.bsky.social) for the beautiful title-page graphics!
Thank you Cancer Discovery (@aacrjournals.bsky.social) for the beautiful title-page graphics!
Reposted by Terkild Brink Buus
Congratulations Terkild and the team👏💪😊 very important new knowledge on the intricacies of this horrible cancer - this new understanding of coexisting yet specialized cancer subclones is a key discovery for a truly targeted treatment in the future !!!!
Bravo 👏👏👏
Bravo 👏👏👏
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
June 30, 2025 at 5:30 PM
Congratulations Terkild and the team👏💪😊 very important new knowledge on the intricacies of this horrible cancer - this new understanding of coexisting yet specialized cancer subclones is a key discovery for a truly targeted treatment in the future !!!!
Bravo 👏👏👏
Bravo 👏👏👏
Reposted by Terkild Brink Buus
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
June 19, 2025 at 11:31 AM
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
June 19, 2025 at 11:31 AM
❗How can a cancer exploit its environment and still resist treatment?
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
✅The answer: co-existing malignant subclones.
Let me walk you through our latest study investigating how divergent evolution drives adaptability, aggressiveness, and drug resistance of T cell cancer. 1/🧵
doi.org/10.1158/2159...
Reposted by Terkild Brink Buus
Now online in Cancer Discovery: Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and Intrinsic Drug Resistance in T Cell Cancer - by @terkild.bsky.social, @niels-odum.bsky.social, and colleagues doi.org/10.1158/2159... @ucph.bsky.social
June 17, 2025 at 1:53 PM
Now online in Cancer Discovery: Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and Intrinsic Drug Resistance in T Cell Cancer - by @terkild.bsky.social, @niels-odum.bsky.social, and colleagues doi.org/10.1158/2159... @ucph.bsky.social
Can bacterial infections make cancer cells resistant to treatment?
In Sézary Syndrome (SS), it turns out they can!
Want to know more? I will summarize some highlights from our study below.
doi.org/10.1182/bloo...
In Sézary Syndrome (SS), it turns out they can!
Want to know more? I will summarize some highlights from our study below.
doi.org/10.1182/bloo...
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome
Enterotoxins from S aureus bacteria induce drug resistance in primary malignant T cells in SS.Targeting bacteria, their toxins, and downstream signaling pa
doi.org
November 19, 2024 at 5:44 PM
Can bacterial infections make cancer cells resistant to treatment?
In Sézary Syndrome (SS), it turns out they can!
Want to know more? I will summarize some highlights from our study below.
doi.org/10.1182/bloo...
In Sézary Syndrome (SS), it turns out they can!
Want to know more? I will summarize some highlights from our study below.
doi.org/10.1182/bloo...
Reposted by Terkild Brink Buus
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors.
Itay Tirosh & Mario L. Suva
www.sciencedirect.com/science/arti...
Itay Tirosh & Mario L. Suva
www.sciencedirect.com/science/arti...
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors
Human tumors are intricate ecosystems composed of diverse genetic clones and malignant cell states that evolve in a complex tumor micro-environment. S…
www.sciencedirect.com
November 17, 2024 at 5:00 PM
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors.
Itay Tirosh & Mario L. Suva
www.sciencedirect.com/science/arti...
Itay Tirosh & Mario L. Suva
www.sciencedirect.com/science/arti...
Reposted by Terkild Brink Buus
in case this is useful to someone in this massive platform migration: a starting pack for single-cell omics computational methods
go.bsky.app/GmS1cH
go.bsky.app/GmS1cH
single-cell computational methods
Join the conversation
go.bsky.app
November 15, 2024 at 11:11 AM
in case this is useful to someone in this massive platform migration: a starting pack for single-cell omics computational methods
go.bsky.app/GmS1cH
go.bsky.app/GmS1cH
Any starter packs around for researchers in single-cell method development (not computational), dermatology, inflammatory skin disease, atopic dermatitis or cutaneous T cell lymphoma?
November 19, 2024 at 5:44 PM
Any starter packs around for researchers in single-cell method development (not computational), dermatology, inflammatory skin disease, atopic dermatitis or cutaneous T cell lymphoma?